Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | Q556_V559del |
Impact List | deletion |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT Q556_V559del results in the deletion of four amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 556 to 559 (PMID: 16226710). Q556_V559del has not been characterized, however similar Kit exon 11 deletions are activating (PMID: 9438854, PMID: 15365079), and therefore, is predicted to lead to a gain of Kit protein function. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT exon 11 del KIT Q556_V559del KIT mutant KIT exon11 KIT exon 11 del KIT Q556_V559del |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727434_54727445del12 |
cDNA | c.1666_1677del12 |
Protein | p.Q556_V559delQWKV |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001385292.1 | chr4:g.54727443_54727454del12 | c.1666_1677del12 | p.V556_E559delVVEE | RefSeq | GRCh38/hg38 |
NM_001385286.1 | chr4:g.54727446_54727457del12 | c.1666_1677del12 | p.V556_I559delVEEI | RefSeq | GRCh38/hg38 |
XM_005265741 | chr4:g.54727433_54727444del12 | c.1668_1679del12 | p.Q557_V560delQWKV | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54727434_54727445del12 | c.1666_1677del12 | p.Q556_V559delQWKV | RefSeq | GRCh38/hg38 |
XM_005265740 | chr4:g.54727433_54727444del12 | c.1668_1679del12 | p.Q557_V560delQWKV | RefSeq | GRCh38/hg38 |
XM_005265742 | chr4:g.54727443_54727454del12 | c.1666_1677del12 | p.V556_E559delVVEE | RefSeq | GRCh38/hg38 |
NM_001385288.1 | chr4:g.54727443_54727454del12 | c.1666_1677del12 | p.V556_E559delVVEE | RefSeq | GRCh38/hg38 |
XM_017008178 | chr4:g.54727434_54727445del12 | c.1666_1677del12 | p.Q556_V559delQWKV | RefSeq | GRCh38/hg38 |
XM_017008179 | chr4:g.54727443_54727454del12 | c.1666_1677del12 | p.V556_E559delVVEE | RefSeq | GRCh38/hg38 |
NM_001385284.1 | chr4:g.54727433_54727444del12 | c.1668_1679del12 | p.Q557_V560delQWKV | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54727434_54727445del12 | c.1666_1677del12 | p.Q556_V559delQWKV | RefSeq | GRCh38/hg38 |
NM_001093772 | chr4:g.54727446_54727457del12 | c.1666_1677del12 | p.V556_I559delVEEI | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727434_54727445del12 | c.1666_1677del12 | p.Q556_V559delQWKV | RefSeq | GRCh38/hg38 |
NM_001093772.1 | chr4:g.54727446_54727457del12 | c.1666_1677del12 | p.V556_I559delVEEI | RefSeq | GRCh38/hg38 |
XM_017008180.1 | chr4:g.54727446_54727457del12 | c.1666_1677del12 | p.V556_I559delVEEI | RefSeq | GRCh38/hg38 |
NM_001385290.1 | chr4:g.54727433_54727444del12 | c.1668_1679del12 | p.Q557_V560delQWKV | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727434_54727445del12 | c.1666_1677del12 | p.Q556_V559delQWKV | RefSeq | GRCh38/hg38 |
XM_017008180 | chr4:g.54727446_54727457del12 | c.1666_1677del12 | p.V556_I559delVEEI | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54727434_54727445del12 | c.1666_1677del12 | p.Q556_V559delQWKV | RefSeq | GRCh38/hg38 |
XM_017008179.1 | chr4:g.54727443_54727454del12 | c.1666_1677del12 | p.V556_E559delVVEE | RefSeq | GRCh38/hg38 |
NM_001093772.2 | chr4:g.54727446_54727457del12 | c.1666_1677del12 | p.V556_I559delVEEI | RefSeq | GRCh38/hg38 |
XM_005265741.1 | chr4:g.54727433_54727444del12 | c.1668_1679del12 | p.Q557_V560delQWKV | RefSeq | GRCh38/hg38 |
XM_005265740.1 | chr4:g.54727433_54727444del12 | c.1668_1679del12 | p.Q557_V560delQWKV | RefSeq | GRCh38/hg38 |
XM_005265742.3 | chr4:g.54727443_54727454del12 | c.1666_1677del12 | p.V556_E559delVVEE | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|